We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.75 | 1,710,459 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.70 | 2.80 | 2.75 | 2.75 | 2.75 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 13.09M | USD -33.29M | USD -0.0429 | -0.64 | 21.32M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:41:10 | O | 195,570 | 2.70 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 06/12/2024 | 14:35 | ALNC |  Shield Therapeutics to raise USD10.0 million via AOP subscription |
| 06/12/2024 | 11:31 | UK RNS | Shield Therapeutics PLC RetailBook Offer |
| 06/12/2024 | 11:30 | UK RNS | Shield Therapeutics PLC Subscription by AOP Health to raise US$10 million |
| 21/11/2024 | 14:22 | ALNC | Shield Therapeutics shares up on strong October sales |
| 21/11/2024 | 07:00 | UK RNS | Shield Therapeutics PLC Business Update |
| 29/10/2024 | 14:34 | ALNC | Shield Therapeutics shares slide as it expands financing arrangement |
| 29/10/2024 | 07:00 | UK RNS | Shield Therapeutics PLC Q3 Trading Update |
| 25/9/2024 | 06:00 | UK RNS | Shield Therapeutics PLC Results from Phase 3 paediatric study |
| 04/9/2024 | 10:39 | ALNC | Shield Therapeutics revenue triples, but cost rises widen annual loss |
| 04/9/2024 | 06:00 | UK RNS | Shield Therapeutics PLC Interim results |
Shield Therapeutics (STX) Share Charts1 Year Shield Therapeutics Chart |
|
1 Month Shield Therapeutics Chart |
Intraday Shield Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/12/2024 | 11:01 | Shield Therapeutics: poised for a US licensing deal | 15,577 |
| 01/11/2024 | 11:41 | Dilution | 1 |
| 30/10/2024 | 12:46 | Dilution | - |
| 09/9/2024 | 14:12 | Shield therapeutics what next? | 1,983 |
| 28/8/2024 | 17:09 | Exceptionally Strong Q2 | 30 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-13 17:02:23 | 2.70 | 195,570 | 5,280.39 | O |
| 2024-12-13 17:02:23 | 2.70 | 195,570 | 5,280.39 | O |
| 2024-12-13 16:41:11 | 2.70 | 195,570 | 5,280.39 | O |
| 2024-12-13 15:37:50 | 2.70 | 50,000 | 1,350.50 | O |
| 2024-12-13 15:05:28 | 2.75 | 85,000 | 2,337.50 | O |
| Top Posts |
|---|
Posted at 14/12/2024 08:20 by Shield Therapeutics Daily Update Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 2.75p.Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £21,324,307. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.64. This morning STX shares opened at 2.75p |
Posted at 11/12/2024 05:31 by purchaseatthetop “Fort i sold up 6 to 8 weeks ago, it took 2 weeks to get out of holding, no liquidity here, on the upside ended up with a free carry of xxx shares.”Helps explain Pwhites question about who is selling to keep the price down. Not AOP but bored or disillusioned holders who bought very low. “Think BOD are fighting a battle lost against AOP and loan SWP” Loan SWK is within covenants and interest being paid with capital repayments starting Q1 27 when it will be chucking out cash like crazy. Not a problem. AOP are on our side. Without them we would all be screwed. That is clear. “Equity issue was 4p then all changed to 3p - No explanation in RNS’s about change, so a big ?” Why would AOP pay a 40% premium now that the share price drifted from 3.85p to 2.85p? They still pay a 5.3% premium to the market price. Not discounted! Any PI can buy at a better price than that now. I have added four times since mid Nov at 2.85p odd. We have two aces to play: 1) Paediatric indication H1 25 with luck. Suddenly a large number of new pent up demand for under 18s will boost the sales figures accelerating growth. 2) Sallyport invoice factoring. At 30/6/24 the cash received in advance was $6.8m on sales in the quarter of about $7.5m. STX get about 90% of invoice value on issue and then repay when cash collected after 90 days. Then they pay Viatris etc their share. The advance paid balance would have been about the same end Q3 24 as sales only grew marginally. Q4 24 should see US product sales of around 51k at $220 so $11m. That is an extra $3.5m of revenue to get advance cash from. So maybe $3m more. This is the equivalent of obtaining extra funding. So if they get the £1m retail book away, plus this $3m, plus the AOP $10m, they actually have raised nearly $15m. And further sales growth simply increases the Sallyport funding to cash breakeven. |
Posted at 10/12/2024 13:39 by purchaseatthetop 30/10/24 share price was 2.9pSince then we have had the business update saying average prescription revenue has risen to $220 from $167 in Q3 24 (rise of 33%), that 2024 target of $31m will be hit, and AOP have confirmed another $10m cash at 3p. Share price to buy now 2.84p! Well, more for me tomorrow. |
Posted at 08/12/2024 09:45 by pwhite73 patt - "Why should they pay a 35% premium now that the share price has fallen."Because they are the ones who have been shorting the stock down so they get more shares for their $10 million. Where do you think all the 100k, 200k and 300k sells have been coming from keeping the price in the 2.70p - 2.90p range. The closing of the $10 million 3p deal would also include the closing of their short. You see that the share price is down is of no concern to AOP what matters to them is control of the company because once the SWK secured loan is satisfied they will take over STX. When they take over they need offer only the highest price paid in the last twelve months. This is why investors are delusional if they think the share price is going to soar once STX gets paediatric approval, Chinese approval or makes greater traction in the prescribed iron deficiency market. AOP will ensure the share price remains deflated. Given the lack of normal liquidity I doubt STX will see 2025 out as a listed concern. Be careful. |
Posted at 20/11/2024 18:41 by base7 As our share price drifts back towards its lows after yte brief excitement ,my thoughts turn back,again to the previus Proactive when our CEO hinted,in response to my question about Director share buying,that they were previously prohibited but could now buy shares .......yet none of them havent.If they believe in the potential of the company he & Santosh are running, they would surely be buying as many shares as they could afford if they consider our share price to materially understate our prospective value. Those in the know are not buying which emits a very poor signal. |
Posted at 15/11/2024 10:43 by purchaseatthetop “Although there had been some recovery in the share price to ca.5.Op, following the 3Q'24 trading update, the market has become more concerned about the continuing commercial risk and the debate about gross cash. This was exacerbated by the updated view that Shield needed to agree a share subscription for a minimum of $10m from its major shareholder, AOP Health, to get it to cashflow-breakeven. The market needs to see further benefits of the enlarged sales team in each sequential quarter in order to have the confidence to rerate the shares.”Seems accurate enough. Whether the extra risk means the share price should halve when the Rx seems just below $200 now when it was $119 a year ago and prescriptions have doubled in a year! The market seems to be assuming more failures by the new lesdership just like the Madison crew. Maybe not this time. |
Posted at 09/11/2024 10:42 by pwhite73 patt - "But rest assured, only SWK have security. Not AOP."Yes having studied the finals again I agree. However that AOP is driving the share price down to takeover the company on the cheap I still maintain. And lets not forget STX has already rejected one offer from AOP. RNS 04/05/2023 - "The Mandatory Offer Price of 6.20 pence per Shield Share is equal to the highest price at which AOP or its concert parties have acquired Shield Shares over the 12 months prior to the date of this Announcement." "The Recommending Shield Directors are recommending Shield Shareholders do not accept the Mandatory Offer, but do not view the Mandatory Offer as being hostile." I'm doing some research on SWK and AOP to see if there is a link as they both appear to be in the same line of business similar to Bergen and New Tech if you know what I mean. |
Posted at 09/11/2024 10:02 by pwhite73 zeus19 - "How does that work? The covenants are with SWK."I don't think you quite understand that financial arrangement and what has proceeded since. 1. The SWK covenants over STX assets is conditional on STX repaying the AOP loan and AOP releasing its ownership over the IP and other assets including Accrufer. 2. The SWK debt facility was entered into on 28/09/2023 it matures on 28/09/2028. Its important to remember its only an available debt facility that the company can draw on should it need to. I am not aware it has drawn on the debt facility as yet. 3. AOP have effectively said NO to the debt facility. What they have said to STX is - "as we are your largest shareholder if you need any money to progress Accrufer and other projects you will borrow it from us not SWK". 4. Hence RNS 03/07/2024 - "Shield Enters into $5.7 million Milestone Monetization Agreement with AOP" 5. Hence RNS 29/10/2024 - "and the entering into of a non-binding term sheet with AOP Health International Management AG ("AOP Health") for the potential provision of $10 million of new equity." 5. Now this is also extremely important. RNS 03/07/2024 - "Further, if the Approval Milestone has not been triggered by 31 December 2026, or in the event the Agreement is terminated, including at Shield's election or due to a breach by Shield of its terms, the Advance plus accrued interest and fees at the interest rate of SOFR+9.25% (calculated from the date of the Advance until the day of payment) and an exit fee of 6.5% of the Advance will be payable by Shield to AOP. The Advance will be secured inter alia by AOP's right to receive the ASK Approval Milestone." Please accept my apologies for the long winded post but its important retail shareholders understand why the share price is so low and in AOP's interest for STX to default which leaves them owning STX and all its assets. |
Posted at 02/11/2024 08:54 by pwhite73 patt - "This support is at 4p. Which is 33% premium to existing share price!"An investor can't increase a share price by subscribing for shares at a higher price than the current market value. But an investor can decrease a share price by subscribing for shares at a lower price than the current market value. |
Posted at 30/10/2024 19:24 by qipincha The 4% growth comparing to Q2 was not right. if they purely compare US revenue, the Q2 income should be 6.2m. So this will give a 15% growth of US revenue and 20% growth of subscription. Also, Q3 report has not take into account of milestone income. if all other income are considered, the growth will be more than 20%!Although I understand the company has a very tight cash budget, I am not sure why they need so much money. Their currently quarterly spend is 13.8 and potential quarterly spend will be 12.6m with proposed 10% cost saving. Given they already know Q4 of 11.5m income, they are not far from breakeven. Ok, let's say purely consider US income without other income such as milestone (worst case scenario), the Q4 US revenue will be 9.5m, Q1 2025 will be approx 11m and Q2 2025, the US revenue will be 12m+ (with a model using a growth rate of 15%). Their prediction to achieve positive income by the end of 2025, is a piece of cake! with the current cash level of 7.1m, the extra 10m give the company a huge headroom (at least 5m surplus). Personally, I feel this is more than enough. So, when the fund raising is done and dusted, the share price is expected to take off. Q4 update (which will be 11.5m, a 43% increase comparing to Q3) should further support the share price. |
Posted at 30/10/2024 18:04 by qipincha Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some ScrutinyThe Shield Therapeutics plc (LON:STX) share price has softened a substantial 28% over the previous 30 days, handing back much of the gains the stock has made lately. The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 45% in that time. Since its price has dipped substantially, Shield Therapeutics may be sending very bullish signals at the moment with its price-to-sales (or "P/S") ratio of 1.6x, since almost half of all companies in the Pharmaceuticals industry in the United Kingdom have P/S ratios greater than 4.7x and even P/S higher than 8x are not unusual. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited. How Has Shield Therapeutics Performed Recently? Shield Therapeutics certainly has been doing a good job lately as it's been growing revenue more than most other companies. It might be that many expect the strong revenue performance to degrade substantially, which has repressed the share price, and thus the P/S ratio. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price. Is There Any Revenue Growth Forecasted For Shield Therapeutics? Shield Therapeutics' P/S ratio would be typical for a company that's expected to deliver very poor growth or even falling revenue, and importantly, perform much worse than the industry. Retrospectively, the last year delivered an exceptional 224% gain to the company's top line. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. So we can start by confirming that the company has done a tremendous job of growing revenue over that time. Shifting to the future, estimates from the three analysts covering the company suggest revenue should grow by 171% over the next year. Meanwhile, the rest of the industry is forecast to only expand by 8.6%, which is noticeably less attractive. With this in consideration, we find it intriguing that Shield Therapeutics' P/S sits behind most of its industry peers. Apparently some shareholders are doubtful of the forecasts and have been accepting significantly lower selling prices. hxxps://simplywall.s |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
